Resources from the same session
LBA51 - Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Presenter: Jordi Remon Masip
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
Presenter: Julien Mazieres
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA53 - ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
Presenter: Zofia Piotrowska
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
Presenter: Mustafa Ozguroglu
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
972O - Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
Presenter: Gerard Zalcman
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA54 and 972O
Presenter: Martin Reck
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: NSCLC, metastatic
Resources:
Slides
Webcast